Lycera partners with Merck to discover, develop and commercialize small molecules against the retinoic acid related orphan receptor (ROR) gamma for autoimmune diseases

Lycera Corp.

U.S. / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Merck & Co. Inc.

U.S. / Large-Cap Biopharma (>=$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced